Scarica l'app Stockscreener
18.70
10.72%
1.81
Pre-mercato:
18.11
-0.59
-3.16%
Precedente Chiudi:
$16.89
Aprire:
$17.02
Volume 24 ore:
355.37K
Relative Volume:
1.43
Capitalizzazione di mercato:
$830.33M
Reddito:
-
Utile/perdita netta:
-
Rapporto P/E:
-
EPS:
-
Flusso di cassa netto:
-
1 W Prestazione:
+10.26%
1M Prestazione:
-22.98%
6M Prestazione:
+0.00%
1 anno Prestazione:
+0.00%
Intervallo 1D:
$16.75
$19.13
Intervallo di 1 settimana:
$16.40
$19.13
Portata 52W:
$15.86
$28.99
Septerna Inc Stock (SEPN) Company Profile
Confronta SEPN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
SEPN
Septerna Inc
|
18.70 | 830.33M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Septerna Inc Stock (SEPN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-19 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-11-19 | Iniziato | JP Morgan | Overweight |
| 2024-11-19 | Iniziato | TD Cowen | Buy |
| 2024-11-19 | Iniziato | Wells Fargo | Overweight |
Septerna Inc Borsa (SEPN) Ultime notizie
Septerna to Introduce Groundbreaking GPCR Drug Discovery Innovations - Defense World
Septerna (NASDAQ:SEPN) Sets New 52-Week Low – Here’s What Happened - Defense World
Septerna (NASDAQ:SEPN) Sets New 12-Month LowTime to Sell? - MarketBeat
Septerna (NASDAQ:SEPN) Trading Down 8.5%Here's Why - MarketBeat
Septerna (NASDAQ: SEPN) Appoints Gil Labrucherie as Chief Financial Officer - Defense World
Third Rock-backed Maze Therapeutics reveals profit in US IPO filing - Marketscreener.com
Septerna appoints new CFO to bolster financial strategy By Investing.com - Investing.com Australia
Septerna (NASDAQ:SEPN) Shares Gap DownTime to Sell? - MarketBeat
Septerna Expands Leadership with Appointment of Industry Veteran Gil Labrucherie as Chief Financial Officer - The Manila Times
Septerna Brings in Gil Labrucherie as Finance Chief - MarketWatch
Septerna appoints new CFO to bolster financial strategy - Investing.com
Septerna Names Biotech Veteran Gil Labrucherie as CFO, Brings $1.5B Capital Raising Success - StockTitan
Septerna (NASDAQ:SEPN) Trading 7.7% HigherShould You Buy? - MarketBeat
Septerna initiated with an Overweight at JPMorgan - MSN
Septerna (NASDAQ:SEPN) Shares Down 5%Time to Sell? - MarketBeat
Septerna (NASDAQ:SEPN) Sets New 52-Week High – Should You Buy? - Defense World
Septerna (NASDAQ:SEPN) Trading Up 8.4%Time to Buy? - MarketBeat
Septerna to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Septerna to Present GPCR Drug Discovery Pipeline at J.P. Morgan Healthcare Conference 2025 - StockTitan
Vertex Global reports ten IPOs, acquisitions worldwide in 2024 - Tech in Asia
Septerna, Inc.’s (NASDAQ:SEPN) Quiet Period Set To Expire on December 4th - Defense World
New MRGPRX2 antagonists disclosed in Septurna patent - BioWorld Online
Cantor Fitzgerald Weighs in on Septerna FY2024 Earnings - Defense World
Analysts Offer Predictions for Septerna FY2024 Earnings - MarketBeat
Septerna, Inc. Reports Q3 2024 Financials and Progress - Yahoo Finance
Septerna (NASDAQ:SEPN) Coverage Initiated at Wells Fargo & Company - Defense World
Cantor Fitzgerald Begins Coverage on Septerna (NASDAQ:SEPN) - Defense World
Septerna (NASDAQ:SEPN) Coverage Initiated at TD Cowen - Defense World
Septerna started by J.P. Morgan at overweight, GPCR platform cited - MSN
Septerna Inc. (SEPN) reports earnings - Quartz
Septerna proposes terms for upsized $175M IPO - MSN
Septerna Shares Fall 7% After Wider 3Q Loss - MarketWatch
Septerna Reports Third Quarter 2024 Financial Results and Recent Business Highlights - The Manila Times
Septerna Advances Key Drug Trial, Reports $137.5M Cash Position After Successful IPO | SEPN Stock News - StockTitan
Cantor launches Septerna stock coverage, highlighting platform value and growth in GPCR drug development - Investing.com Nigeria
TD Cowen optimistic on Septerna stock as preclinical data fuels confidence - Investing.com Canada
JPMorgan bullish on Septerna stock—pipeline strategy drives optimism - Investing.com India
Septerna Poised For Biopharma Breakthrough: Analysts Cite GPCR Innovation And 2025 Milestones - AOL
Septerna started by J.P. Morgan at overweight, GPCR platform cited (NASDAQ:SEPN) - Seeking Alpha
This Apollo Global Management Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Tuesday - Benzinga
Septerna (NASDAQ:SEPN) Coverage Initiated at Cantor Fitzgerald - MarketBeat
Septerna (NASDAQ:SEPN) Now Covered by TD Cowen - MarketBeat
Septerna (NASDAQ:SEPN) Earns Overweight Rating from Analysts at JPMorgan Chase & Co. - MarketBeat
Septerna (NASDAQ:SEPN) Earns Overweight Rating from Analysts at Wells Fargo & Company - MarketBeat
JPMorgan bullish on Septerna stock—pipeline strategy drives optimism By Investing.com - Investing.com Canada
RA Capital Management's Strategic Investment in Septerna Inc - GuruFocus.com
Buffett Still Building This Stake, Plus Huge Insider Buy in Biotech IPO - 24/7 Wall St.
Wednesday's Insider Activity: Top Buys and Sells in US Stocks By Investing.com - Investing.com Australia
Nasdaq debutante Septerna swells its IPO to $331m - pharmaphorum
Septerna (NASDAQ:SEPN) Files Amendment and Restatement of Certificate of Incorporation and Bylaws - Defense World
Septerna Inc Azioni (SEPN) Dati Finanziari
Non sono disponibili dati finanziari per Septerna Inc (SEPN). Controlla altri titoli per ulteriori informazioni.
Reddito
Reddito netto
Flusso di cassa
EPS
4.81%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):